Bayer: 5 new Phase III drugs expected in 2015

Share this article:

Bayer said Tuesday that it is accelerating its pipeline and expects to have five drugs in Phase III testing in 2015. The drug maker said in a statement that the drugs will swell its oncology, cardiology and women's health list of experimental treatments.

This is in addition to working on expanding the list of indications for drugs including heart drug Xarelto, cancer medication Xofigo and eye treatment Eylea.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.